11/25
09:08 am
ctmx
CytomX Therapeutics to Present at Upcoming December Investor Conferences [Yahoo! Finance]
Low
Report
CytomX Therapeutics to Present at Upcoming December Investor Conferences [Yahoo! Finance]
11/25
08:00 am
ctmx
CytomX Therapeutics to Present at Upcoming December Investor Conferences
Medium
Report
CytomX Therapeutics to Present at Upcoming December Investor Conferences
11/22
09:23 am
ctmx
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike [Yahoo! Finance]
Low
Report
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike [Yahoo! Finance]
11/18
09:43 am
ctmx
CytomX Therapeutics: Leaning Into The Hype, But What's Next? [Seeking Alpha]
Medium
Report
CytomX Therapeutics: Leaning Into The Hype, But What's Next? [Seeking Alpha]
11/13
08:00 am
ctmx
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
Medium
Report
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
11/11
08:09 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) had its price target raised by analysts at HC Wainwright from $5.00 to $10.00. They now have a "buy" rating on the stock.
11/9
07:03 pm
ctmx
CytomX Therapeutics (CTMX): Assessing Valuation After Phase 1 CX-801 Data Preview at SITC Annual Meeting [Yahoo! Finance]
High
Report
CytomX Therapeutics (CTMX): Assessing Valuation After Phase 1 CX-801 Data Preview at SITC Annual Meeting [Yahoo! Finance]
11/7
11:30 pm
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
High
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
11/6
05:42 pm
ctmx
CytomX Therapeutics (CTMX) Is Up 29.1% After Promising CX-801 Phase 1 Biomarker Data Release [Yahoo! Finance]
Medium
Report
CytomX Therapeutics (CTMX) Is Up 29.1% After Promising CX-801 Phase 1 Biomarker Data Release [Yahoo! Finance]
11/6
04:39 pm
ctmx
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/6
04:10 pm
ctmx
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
High
Report
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/4
10:11 am
ctmx
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Low
Report
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
11/4
09:15 am
ctmx
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Medium
Report
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/30
11:45 pm
ctmx
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT [Yahoo! Finance]
Low
Report
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT [Yahoo! Finance]
10/30
08:00 am
ctmx
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
10/22
12:51 am
ctmx
Will CytomX Therapeutics' (CTMX) New Business Chief Reshape Its Growth Strategy or Reinforce Stability? [Yahoo! Finance]
Medium
Report
Will CytomX Therapeutics' (CTMX) New Business Chief Reshape Its Growth Strategy or Reinforce Stability? [Yahoo! Finance]
10/21
06:02 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Medium
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
10/20
04:05 pm
ctmx
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
Medium
Report
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
10/13
11:45 pm
ctmx
CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible [Seeking Alpha]
Neutral
Report
CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible [Seeking Alpha]
10/6
11:22 am
ctmx
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure [Seeking Alpha]
Low
Report
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure [Seeking Alpha]
9/26
08:44 am
ctmx
Why CytomX Therapeutics Stock Was Skyrocketing This Week [Yahoo! Finance]
Low
Report
Why CytomX Therapeutics Stock Was Skyrocketing This Week [Yahoo! Finance]
9/23
06:11 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
9/22
06:34 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
CytomX Therapeutics (NASDAQ:CTMX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
9/18
06:44 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
9/17
08:05 am
ctmx
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC. They now have a $3.50 price target on the stock.
Low
Report
CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC. They now have a $3.50 price target on the stock.